Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Previous studies suggested that CTLA4 polymorphism (rs5742909) is associated with susceptibility to cervical cancer. In the present study, we performed a meta-analysis to systematically summarize the possible association between rs5742909 and the risk for cervical cancer. We conducted a search of case–control studies on the associations of rs5742909 with susceptibility to cervical cancer in PubMed, EMBASE, ISI Web of Science, Cochrane Central Register of Controlled Trials, Wanfang database in China, and Chinese National Knowledge Infrastructure databases. We extracted the data from eligible studies for meta-analysis. The association of cervical cancer risk with rs5742909 was estimated by pooled odds ratios (ORs) and 95 % confidence intervals (95 % CIs). There were four studies on rs5742909 and cervical cancer in our meta-analysis. Our results suggested that both T allele frequency (OR = 1.63, 95 % CI 1.06–2.50; P = 0.03) and (TT + CT) genotype distribution (OR = 1.72, 95 % CI 1.07–2.77; P = 0.03) of the rs5742909 were associated with risk for cervical cancer. This meta-analysis suggests that rs5742909 is associated with the risk of cervical cancer. Well-designed studies with larger sample size and more ethnic groups are required to further validate the results.
Literatur
1.
2.
Zurück zum Zitat Xu Q, Xue F, Yuan B, Zhang L, Li J, He Z. The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population. Cancer Biomark. 2012;11(4):147–53.PubMed Xu Q, Xue F, Yuan B, Zhang L, Li J, He Z. The interaction between RAGE gene polymorphisms and HPV infection in determining the susceptibility of cervical cancer in a Chinese population. Cancer Biomark. 2012;11(4):147–53.PubMed
3.
Zurück zum Zitat Bodelon C, Madeleine MM, Johnson LG, Du Q, Malkki M, Petersdorf EW, et al. Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case–control study. Gynecol Oncol. 2012;124(3):525–8.PubMedCentralPubMedCrossRef Bodelon C, Madeleine MM, Johnson LG, Du Q, Malkki M, Petersdorf EW, et al. Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case–control study. Gynecol Oncol. 2012;124(3):525–8.PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Sharma S, Sharma A, Kumar S, Sharma SK, Ghosh B. Association of TNF haplotypes with asthma, serum IgE levels, and correlation with serum TNF-alpha levels. Am J Respir Cell Mol Biol. 2006;35(4):488–95.PubMedCrossRef Sharma S, Sharma A, Kumar S, Sharma SK, Ghosh B. Association of TNF haplotypes with asthma, serum IgE levels, and correlation with serum TNF-alpha levels. Am J Respir Cell Mol Biol. 2006;35(4):488–95.PubMedCrossRef
5.
Zurück zum Zitat Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2(3):145–52.PubMedCrossRef Ligers A, Teleshova N, Masterman T, Huang WX, Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001;2(3):145–52.PubMedCrossRef
6.
Zurück zum Zitat Bergin AM, Balder B, Kishore S, Sward K, Hahn-Zoric M, Lowhagen O, et al. Common variations in the IL4R gene affect splicing and influence natural expression of the soluble isoform. Hum Mutat. 2006;27(10):990–8.PubMedCrossRef Bergin AM, Balder B, Kishore S, Sward K, Hahn-Zoric M, Lowhagen O, et al. Common variations in the IL4R gene affect splicing and influence natural expression of the soluble isoform. Hum Mutat. 2006;27(10):990–8.PubMedCrossRef
7.
Zurück zum Zitat Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol. 1996;8(6):822–30.PubMedCrossRef Tivol EA, Schweitzer AN, Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol. 1996;8(6):822–30.PubMedCrossRef
8.
Zurück zum Zitat Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7(4):445–50.PubMedCrossRef Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997;7(4):445–50.PubMedCrossRef
9.
Zurück zum Zitat Guzman VB, Yambartsev A, Goncalves-Primo A, Silva ID, Carvalho CR, Ribalta JC, et al. New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet. 2008;17(12):1838–44.PubMedCrossRef Guzman VB, Yambartsev A, Goncalves-Primo A, Silva ID, Carvalho CR, Ribalta JC, et al. New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet. 2008;17(12):1838–44.PubMedCrossRef
10.
Zurück zum Zitat Rahimifar S, Erfani N, Sarraf Z, Ghaderi A. ctla-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol. 2010;119(1):136–9.PubMedCrossRef Rahimifar S, Erfani N, Sarraf Z, Ghaderi A. ctla-4 gene variations may influence cervical cancer susceptibility. Gynecol Oncol. 2010;119(1):136–9.PubMedCrossRef
11.
Zurück zum Zitat Jiang L, Luo RY, Zhang W, Wang LR, Wang F, Cheng YX. Single nucleotide polymorphisms of CTLA4 gene and their association with human cervical cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011;28(3):313–7.PubMed Jiang L, Luo RY, Zhang W, Wang LR, Wang F, Cheng YX. Single nucleotide polymorphisms of CTLA4 gene and their association with human cervical cancer. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011;28(3):313–7.PubMed
12.
Zurück zum Zitat Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis. 2007;28(6):1237–40.PubMedCrossRef Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, et al. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis. 2007;28(6):1237–40.PubMedCrossRef
13.
Zurück zum Zitat Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116(3):544–8.PubMedCrossRef Ivansson EL, Juko-Pecirep I, Gyllensten UB. Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol. 2010;116(3):544–8.PubMedCrossRef
14.
Zurück zum Zitat Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, Jonkisz A, Tomkiewicz A, et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol. 2010;71(2):195–200.PubMedCrossRef Pawlak E, Karabon L, Wlodarska-Polinska I, Jedynak A, Jonkisz A, Tomkiewicz A, et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol. 2010;71(2):195–200.PubMedCrossRef
15.
Zurück zum Zitat Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein. Genes Immun. 2002;3(4):233–4.PubMedCrossRef Wang XB, Zhao X, Giscombe R, Lefvert AK. A CTLA-4 gene polymorphism at position −318 in the promoter region affects the expression of protein. Genes Immun. 2002;3(4):233–4.PubMedCrossRef
16.
Zurück zum Zitat Suppiah V, Alloza I, Heggarty S, Goris A, Dubois B, Carton H, et al. The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol. 2005;164(1–2):148–53.PubMedCrossRef Suppiah V, Alloza I, Heggarty S, Goris A, Dubois B, Carton H, et al. The CTLA4 +49 A/G*G-CT60*G haplotype is associated with susceptibility to multiple sclerosis in Flanders. J Neuroimmunol. 2005;164(1–2):148–53.PubMedCrossRef
17.
Zurück zum Zitat Vaidya B, Pearce SH, Charlton S, Marshall N, Rowan AD, Griffiths ID, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford). 2002;41(2):180–3.CrossRef Vaidya B, Pearce SH, Charlton S, Marshall N, Rowan AD, Griffiths ID, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford). 2002;41(2):180–3.CrossRef
18.
Zurück zum Zitat Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J, et al. Association of the CTLA4 promoter region (−1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 2003;4(2):132–7.PubMedCrossRef Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J, et al. Association of the CTLA4 promoter region (−1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 2003;4(2):132–7.PubMedCrossRef
19.
Zurück zum Zitat Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A. CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diab Res Clin Pract. 2005;68(2):111–6.CrossRef Mojtahedi Z, Omrani GR, Doroudchi M, Ghaderi A. CTLA-4 +49 A/G polymorphism is associated with predisposition to type 1 diabetes in Iranians. Diab Res Clin Pract. 2005;68(2):111–6.CrossRef
20.
Zurück zum Zitat Baniasadi V, Narain N, Goswami R, Das SN. Promoter region − 318 C/T and − 1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Tissue Antigens. 2006;67(5):383–9.PubMedCrossRef Baniasadi V, Narain N, Goswami R, Das SN. Promoter region − 318 C/T and − 1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Tissue Antigens. 2006;67(5):383–9.PubMedCrossRef
21.
Zurück zum Zitat Wang L, Li D, Fu Z, Li H, Jiang W. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer. 2007;7:173.PubMedCentralPubMedCrossRef Wang L, Li D, Fu Z, Li H, Jiang W. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer. 2007;7:173.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol. 2007;22(12):2283–7.PubMedCrossRef Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ, Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol. 2007;22(12):2283–7.PubMedCrossRef
23.
Zurück zum Zitat Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, et al. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep. 2010;37(1):515–20.PubMedCrossRef Hou R, Cao B, Chen Z, Li Y, Ning T, Li C, et al. Association of cytotoxic T lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep. 2010;37(1):515–20.PubMedCrossRef
Metadaten
Titel
Association of CTLA4 gene polymorphism (rs5742909) with cervical cancer: a meta-analysis
Publikationsdatum
01.02.2014
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1221-1

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.